CuraGen Corp. has initiated patient dosing in a Phase II trial evaluating a single dose of velafermin for the prevention of oral mucositis (OM). This is the second Phase II study of velafermin and is designed to assess the safety and efficacy of velafermin for the prevention of OM in cancer patients receiving high-dose chemotherapy, with or without radiotherapy, in the setting of autologous bone marrow transplantation (BMT). This multi-center, randomized, double-blind, placebo-controlled, P...